Study design and population
This retrospective study was
carried out from January 2014 to November 2018 in Montpellier University
Hospital, France. In this tertiary care institution, all children with
an IH requiring a medical treatment with a beta-blocker are
systematically hospitalized for treatment initiation. In this study, the
hospital discharge database (PMSI, Programme de Medicalisation des
Systemes d’Information) was used for patients screening. The PMSI is a
mandatory national database linked to the social security, in which all
hospitalizations are automatically and prospectively registered. This
database uses a standardized diagnosis coding from the
10th revision of the International Classification of
Diseases (ICD-10). The code associated to the term “haemangioma” (D13)
was used to screen patients and finally only children <2 years
old treated with Hemangiol® were included in the final analysis.